Short answer

Korro Bio, Inc. (KRRO) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $0 (down 100.0% year over year) with net income of −$20M.

Q1 2026 key financials · XBRL

Revenue: $0; −100.0% YoY
Net income: −$20M; +16.1% YoY
EPS (diluted): −$1.69; +32.1% YoY

Source: XBRL data from the Korro Bio, Inc. (KRRO) Q1 2026 10-Q on SEC EDGAR. USD.

Korro Bio, Inc. Q1 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

Revenue $0 versus $2.6M YoY, reflecting paused Novo Nordisk collaboration
Net loss $19.6M versus $23.4M; operating margin not disclosed
KRRO-121 expenses $3.8M versus $3.3M; KRRO-110 expenses fell $5.4M after trial termination
Cash, equivalents and marketable securities $157.1M; operating cash use $16.1M versus $24.5M
$88.2M financing cash inflow; runway expected into second half of 2028
Regulatory filing for KRRO-121 first-in-human trial anticipated second half of 2026

Risk Factors

Clinical-stage setback: KRRO-110 REWRITE trial failed projected protein levels, prompting program termination and AATD transition to GalNAc delivery
Regulatory uncertainty: FDA lacks definitive guidance for RNA-editing oligonucleotides, potentially delaying review and imposing unanticipated requirements
Operational risk: Only nominated development candidate is preclinical KRRO-121, concentrating execution risk ahead of anticipated second-half 2026 filing
Financial risk: $157.1 million cash, equivalents, and marketable securities expected to fund operations into second-half 2028, but no committed additional capital source
Manufacturing risk: Limited oligonucleotide manufacturers and constrained raw-material suppliers could delay clinical supply and development timelines

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Korro Bio, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.

Start free